KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBT Margin (2016 - 2025)

Historic EBT Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 861.6%.

  • Xenon Pharmaceuticals' EBT Margin changed N/A to 861.6% in Q1 2025 from the same period last year, while for Sep 2025 it was 4195.93%, marking a year-over-year change of. This contributed to the annual value of 1327.7% for FY2022, which is 8998200.0% down from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' EBT Margin stood at 861.6%.
  • Xenon Pharmaceuticals' 5-year EBT Margin high stood at 228.88% for Q1 2022, and its period low was 28588.64% during Q3 2022.
  • Moreover, its 3-year median value for EBT Margin was 766.36% (2021), whereas its average is 4736.05%.
  • Over the last 5 years, Xenon Pharmaceuticals' EBT Margin had its largest YoY gain of 1344000bps in 2022, and its largest YoY loss of -282408600bps in 2022.
  • Over the past 3 years, Xenon Pharmaceuticals' EBT Margin (Quarter) stood at 671.13% in 2021, then plummeted by -4160bps to 28588.64% in 2022, then skyrocketed by 97bps to 861.6% in 2025.
  • Its EBT Margin was 861.6% in Q1 2025, compared to 28588.64% in Q3 2022 and 5820.52% in Q2 2022.